Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
about
Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsNeurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approachTargeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic ApproachOpioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial.Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.Optimizing Central Nervous System Drug Development Using Molecular Imaging.Motion Sickness: Current Knowledge and Recent Advance.Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.Are itch and scratching the nausea and vomiting of skin?Commentary on: "Effect of sevoflurane anesthesia on the comprehensive mRNA expression profile of the mouse hippocampus": Postoperative nausea and vomiting conundrum: RNA-seq to the rescue.Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.The preventive effect of the impaired liver function for antiemetic therapy against chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients.In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs.
P2860
Q24200792-DD7D2712-31FA-42BE-8E41-54682525658BQ26472106-61AB4D50-0CE9-4DC6-88BA-8C59D2FCAA6CQ26739681-6307DC88-53D4-49A1-B338-8805BFF9CA6AQ28085005-9000DD14-B4FB-4356-A458-DDA7FC7F6D6FQ36716447-EF1D273A-B8A3-4A3A-8422-BCEE6619EFBDQ36843470-23D7CDC7-5915-450B-958B-325612304227Q37078009-CB690B33-D07E-4CAA-99EC-A4C8F35758A0Q37193219-4BA4AF9A-EAC5-4F37-A693-E523071A7A6AQ37593097-CD10372A-1B1E-4E4D-AB33-73A276F280B7Q38018635-8146FC96-A982-4FEE-BE99-A3832C9D7CA7Q38217456-A7ACAFEC-DAF9-46B1-92A4-6E6BC554E233Q38419418-E3A6C2FC-C16D-41C0-9630-BD6CD10681E7Q38603260-80B0BEC3-B562-4C99-B738-5365A7174341Q38926264-C9801410-C82C-471A-BC7B-85EB009AA4E4Q42242954-4EF43B1A-D7F9-4C76-B731-DB629765D748Q42368547-F3CD40F3-059D-43F0-84D9-4B450C16778EQ44342218-F68C936B-EC4B-4DFF-929E-DE5DE2D736D8Q45163008-63C4BC92-512F-4857-94E4-3E1E5E36B684Q48188853-0F330C27-A9A5-4544-BA4B-E1FB4B10E796Q48267766-F9E421C3-888C-4292-B61D-BACBF9A88D02Q48458955-CB533032-096E-44C9-90FF-E1281A4A796CQ49582181-A43AB382-B986-4AC4-AAFC-FCB60FC6D4B8Q53594362-EF35AB55-91A4-4D46-BD44-F43CBA811A2F
P2860
Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of aprepitant, the ...... y-induced nausea and vomiting.
@en
Development of aprepitant, the ...... y-induced nausea and vomiting.
@nl
type
label
Development of aprepitant, the ...... y-induced nausea and vomiting.
@en
Development of aprepitant, the ...... y-induced nausea and vomiting.
@nl
prefLabel
Development of aprepitant, the ...... y-induced nausea and vomiting.
@en
Development of aprepitant, the ...... y-induced nausea and vomiting.
@nl
P2093
P2860
P1476
Development of aprepitant, the ...... y-induced nausea and vomiting.
@en
P2093
Britta Mattson
David Hughes
Jos Brands
Juan Camilo Arjona Ferreira
Richard Hargreaves
Sandy Mills
P2860
P356
10.1111/J.1749-6632.2011.05961.X
P407
P577
2011-03-01T00:00:00Z